FindTrial
Sign In

Understanding role of tests like claudin 18 and Her2 low in Stomach Cancer and role in treatment

Prevalence of Claudin18.2 positivity and HER2 low status in gastric and gastro-esophageal junction adenocarcinoma- A prospective observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/07/113958
Enrollment
88
Registered
2026-07-14
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C169- Malignant neoplasm of stomach, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

Hospital IMS and SUM Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All histologically confirmed gastric OR GEJ adenocarcinoma Age 18 year to 99 years

Exclusion criteria

Exclusion criteria: Age more than 99 years other histologic subtypes

Design outcomes

Primary

MeasureTime frame
To determine the prevalence of CLDN18 positivity and HER2 low status in gastric and GEJ adenocarcinomaTimepoint: At the end of the enrollment of last patient and before 2 years.—

Secondary

MeasureTime frame
To correlate CLDN 18 with clinicopathologic factors Histological grade weight loss dysphagia pain vomiting reflux obstruction To compare CLDN 18 expression between non metastatic & metastatic Timepoint: At the end of enrollment of last patient & before 2 years—

Countries

India

Contacts

Public ContactSourabh Takkar

IMS and SUM Hospital

drgbiswas@gmail.com9937500878

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026